我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
21
11 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
2010
进行中（未招募）
11
52.4%
已完成
6
28.6%
招募中
4
19.1%
暂无批准数据
- Otsuka Pharmaceutical has acquired worldwide rights to Cantargia's CAN10, an IL-1RAP targeting monoclonal antibody in Phase 1 development for autoimmune diseases, for $33 million upfront. - The deal includes potential milestone payments up to $580 million plus double-digit tiered earn-out payments from global product sales, with transaction expected to close in Q3 2025. - CAN10 uniquely inhibits multiple IL-1 family cytokines (IL-1, IL-33, and IL-36) simultaneously by targeting IL-1RAP, potentially offering next-generation treatment for inflammatory and autoimmune conditions. - The acquisition expands Otsuka's autoimmune disease pipeline and leverages their antibody drug platform through subsidiary Visterra to accelerate development across multiple therapeutic pathways.
